Summary & Overview
HCPCS Q4211: Amnion Bio/Axobiomembrane, Per Square Centimeter
HCPCS Level II code Q4211 denotes an amnion bio or axobiomembrane billed per square centimeter as an add-on supply for use in wound coverage and tissue repair. Nationally, this code matters because it standardizes reporting for biologic membrane products that are used in surgical and wound-care procedures and affects billing clarity when these products are supplied in addition to a primary procedure. Providers, payers, and facilities rely on this code to distinguish the graft material from the base surgical service and to manage coverage determinations and claim adjudication.
Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the code’s clinical context, the typical sites of service where it is administered, common modifiers associated with the code, and where to look for related coding and billing considerations. The publication also outlines benchmarking and reimbursement context where available and highlights policy and coverage topics relevant to biologic grafts. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code Q4211 describes an amnion bio or axobiomembrane supplied per square centimeter and is designated as an add-on item to be listed separately in addition to the primary procedure. The service type is allograft/biologic graft application, typically used to provide a biological membrane for wound coverage, tissue repair, or surgical augmentation.
The typical site of service for application of this product is outpatient clinics, hospital outpatient departments, ambulatory surgery centers, and wound care centers where surgical or procedural application of biologic graft materials occurs.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with a chronic non-healing lower extremity ulcer (history of peripheral arterial disease and diabetes mellitus) presents to a wound care clinic. After debridement of necrotic tissue and optimization of local wound bed conditions, the clinician selects an amnion-derived biologic membrane as an adjunctive graft to promote epithelialization and reduce inflammation. The procedure is performed in an outpatient wound clinic or ambulatory surgery center under local anesthesia. The primary procedure (for example, debridement or graft placement) is reported separately; Q4211 is billed as an add-on charge per square centimeter for the amnion bio/axobiomembrane product applied to the wound. Documentation includes wound measurements (cm2), indication for biologic membrane use, product lot/size, application technique, patient tolerance, and concurrent procedures. Typical follow-up visits document graft integration, wound size reduction, and any complications.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Standard reporting (no modifier) | Use when no special circumstance applies and services are rendered as usual. |
22 |